Effective suicide gene therapy for leukemia in a model of insertional oncogenesis in mice

Molecular Therapy

Volumn 15, Issue 1, 2007, Pages 183-192

  Blumenthal, Martina ^a   Skelton, Dianne ^b   Pepper, Karen A ^b   Jahn, Thomas ^a,b   Methangkool, Emily ^a   Kohn, Donald B ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GANCICLOVIR; PROTEIN SC39; PROTEIN SR39; RETROVIRUS VECTOR; STEM CELL FACTOR RECEPTOR; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SENSITIVITY; GENE INSERTION; GENE LOSS; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LEUKEMIA; LEUKEMIA CELL LINE; MALE; MOLECULAR CLONING; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SUICIDE GENE THERAPY; TREATMENT OUTCOME;

ANIMALS; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GANCICLOVIR; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; LEUKEMIA; MALE; MICE; MICE, INBRED BALB C; ONCOGENES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

MOLONEY MURINE LEUKEMIA VIRUS; MURINAE; SIMPLEXVIRUS;

EID: 33845990294     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300015     Document Type: Article

References (33)

1. Hacein-Bey-Abina, S et al. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 346: 1185-1193.
2. Hacein-Bey-Abina, S et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302: 415-419.
3. Davé, UP, Jenkins, NA and Copeland, NG (2004). Gene therapy insertional mutagenesis insights. Science 303: 333.
4. Kohn, DB, Sadelain, M and Glorioso, JC (2003). Occurance of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 3: 477-488.
5. Shou, Y, Ma, Z, Lu, T and Sorrentino, BP (2006). Unique risk factor for insertional oncogenesis in a mouse model of XSCID gene therapy. Proc Natl Acad Sci USA 103: 11730-11735.
6. Gaspar, HB et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364: 2181-2187.
7. Aiuti, A et al. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296: 2410-2413.
8. Moolten, FL (1994). Drug sensitivity ("suicide") genes for selective cancer chemotherapy. Cancer Gene Ther 1: 279-287.
9. Ram, Z et al. (1997). Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. Nat Med 3: 1354-1361.
10. Wildner, O (1999). In situ use of suicide genes for therapy of brain tumours. Ann Med 31: 421-429.
11. Satoh, T, Irie, A, Egawa, S and Baba, S (2005). In situ gene therapy for prostate cancer. Curr Gene Ther 5: 111-119.
12. Cohen, JL et al. (1997). Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood 89: 4636-4645.
13. Bonini, C et al. (1997). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276: 1719-1724.
14. Tiberghien, P et al. (2001). Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97: 63-72.
15. Baum, C et al. (2003). Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101: 2099-2114.
16. Kitayama, H et al. (1995). Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 85: 790-798.
17. Qasim, W, Thrasher, AJ, Buddle, J, Kinnon, C, Black, ME and Gaspar, HB (2002). T cell transduction and suicide with an enhanced mutant thymidine kinase. Gene Therapy 9: 824-827.
18. Limaye, AP, Corey, L, Koelle, DM, Davis, CL and Boeckh, M (2000). Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356: 645-649.
19. Garin, MI et al. (2001). Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 97: 122-129.
20. Black, ME, Kokoris, MS and Sabo, P (2001). Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res 61: 3022-3026.
21. Chalmers, D et al. (2001). Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. Mol Ther 4: 146-148.
22. Roche Laboratories (2000). Cytovene IV/Cytovene Complete Product Information, p.14. Available at: http://www.rocheusa.com/products/ cytovene/pi.pdf.
23. Morfin, F and Thouvenot, D (2002). Herpes simplex virus resistance to antiviral drugs. J Clin Virol 26: 29-37.
24. Frank, O et al. (2004). Tumor cells escape suicide gene therapy by genetic and epigenetic instability. Blood 104: 3543-3549.
25. Li, Z et al. (2002). Murine leukemia induced by retroviral gene marking. Science 296: 497.
26. Woods, NB, Bottero, V, Schmidt, M, von Kalle, C and Verma, IM (2006). Gene therapy: Therapeutic gene causing lymphoma. Nature 440: 1123.
27. Montini, E et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24: 687-696.
28. Challita, PM, Skelton, D, El-Khoueiry, A, Yu, X, Weinberg, KI and Kohn, DB (1995). Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol 69: 748-755.
29. Robbins, PB et al. (1997). Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells. J Virol 71: 9466-9474.
30. Robbins, PB, Skelton, DC, Yu, X, Halene, S, Leonard, EH and Kohn, DB (1998). Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. Proc Natl Acad Sci USA 95: 10182-10187.
31. Halene, S, Wang, L, Cooper, RM, Bockstoce, DC, Robbins, PB and Kohn, DB (1999). Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector. Blood 94: 3349-3357.
32. Jahn, T, Seipel, P, Urschel, S, Peschel, C and Duyster, J (2002). Role for the adaptor protein Grb10 in the activation of Akt. Mol Cell Biol 22: 979-991.
33. Soneoka, Y et al. (1995). A transient three plasmid expression system for the production of high titre retroviral vectors. Nucleic Acids Res 23: 626-633.